BPC-157 vs Semaglutide

A synthetic 15-amino-acid pentadecapeptide derived from a protein in human gastric juice, widely researched for its effects on soft tissue healing, tendon repair, and gut integrity.

A GLP-1 receptor agonist originally approved for type 2 diabetes and now widely used for chronic weight management, producing 15%+ reductions in body weight over 12 months in clinical trials.

BPC-157 appears to upregulate growth hormone receptor expression, promote angiogenesis through VEGF pathways, and accelerate collagen reorganisation in damaged tissue. Animal models show effects on ligament, tendon, muscle, bone, and gastric mucosa repair.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite via hypothalamic signalling, and enhancing glucose-dependent insulin secretion. The result is sustained calorie reduction without conscious restriction.

250–500 mcg per day (research protocols)

0.25 mg weekly, titrated up to 2.4 mg weekly for weight loss

~4 hours (parenteral)

~7 days

Subcutaneous, Intramuscular, Oral (stable form)

Subcutaneous once weekly, Oral (lower bioavailability)

research-only

approved

£16 · £3.2/mg via Peptides UK

Not yet listed